Adriana C Vidal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3947196/publications.pdf

Version: 2024-02-01

257450 345221 61 1,448 24 36 citations h-index g-index papers 62 62 62 2943 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Maternal cadmium, iron and zinc levels, DNA methylation and birth weight. BMC Pharmacology & Samp; Toxicology, 2015, 16, 20.	2.4	95
2	Maternal Stress, Preterm Birth, and DNA Methylation at Imprint Regulatory Sequences in Humans. Genetics & Epigenetics, 2014, 6, GEG.S18067.	2.5	93
3	Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2015, 21, 756-762.	7.0	91
4	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	2.5	84
5	Associations between Methylation of Paternally Expressed Gene 3 (PEG3), Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. PLoS ONE, 2013, 8, e56325.	2.5	73
6	Erythrocyte folate concentrations, CpG methylation at genomically imprinted domains, and birth weight in a multiethnic newborn cohort. Epigenetics, 2014, 9, 1120-1130.	2.7	73
7	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 252-259.	3.9	71
8	HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes and Control, 2014, 25, 1055-1062.	1.8	62
9	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	7.0	46
10	Metabolic syndromeâ€like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (<scp>REDUCE</scp>) study. BJU International, 2015, 115, 736-743.	2.5	35
11	Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infectious Agents and Cancer, 2011, 6, 20.	2.6	33
12	Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. Frontiers in Immunology, 2018, 9, 2925.	4.8	32
13	Obesity, race, and longâ€ŧerm prostate cancer outcomes. Cancer, 2020, 126, 3733-3741.	4.1	32
14	The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. Cancer Causes and Control, 2014, 25, 1029-1035.	1.8	31
15	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	4.1	30
16	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	1.8	30
17	Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget, 2017, 8, 94900-94909.	1.8	29
18	Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prevention Research, 2015, 8, 1055-1060.	1,5	28

#	Article	IF	CITATIONS
19	Natural Killer Cell-Endothelial Cell Interactions in Xenotransplantation. Immunologic Research, 2000, 22, 165-176.	2.9	27
20	Maternal BMI, IGF-I Levels, and Birth Weight in African American and White Infants. International Journal of Pediatrics (United Kingdom), 2013, 2013, 1-7.	0.8	27
21	Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. European Urology, 2017, 72, 78-83.	1.9	27
22	Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2014, 20, 5331-5338.	7.0	26
23	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. European Urology, 2016, 69, 885-891.	1.9	26
24	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. Journal of Urology, 2020, 203, 331-337.	0.4	25
25	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research, 2017, 10, 319-326.	1.5	23
26	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer and Prostatic Diseases, 2020, 23, 419-428.	3.9	22
27	Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer, 2012, 12, 389.	2.6	20
28	The Association of Exercise with Both Erectile and Sexual Function in Black and White Men. Journal of Sexual Medicine, 2015, 12, 1202-1210.	0.6	20
29	Associations between Intake of Folate, Methionine, and Vitamins B-12, B-6 and Prostate Cancer Risk in American Veterans. Journal of Cancer Epidemiology, 2012, 2012, 1-9.	1.1	17
30	Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. Scientific Reports, 2015, 5, 15341.	3.3	15
31	Carbohydrate intake, glycemic index and prostate cancer risk. Prostate, 2015, 75, 430-439.	2.3	15
32	IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes. Infectious Agents and Cancer, 2015, 10, 10.	2.6	15
33	Obese patients with castrationâ€resistant prostate cancer may be at a lower risk of allâ€cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	2.5	15
34	Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiology, 2019, 62, 101578.	1.9	14
35	Dietary inflammatory index (DII) and risk of prostate cancer in a case–control study among Black and White US Veteran men. Prostate Cancer and Prostatic Diseases, 2019, 22, 580-587.	3.9	14
36	Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	2.5	12

#	Article	IF	CITATIONS
37	PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 238-244.	3.9	12
38	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. Journal of Urology, 2016, 196, 715-720.	0.4	11
39	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. Anticancer Research, 2020, 40, 1459-1462.	1.1	11
40	Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Scientific Reports, 2017, 7, 43551.	3.3	10
41	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	1.8	10
42	DNA methylation of imprinted gene control regions in the regression of lowâ€grade cervical lesions. International Journal of Cancer, 2018, 143, 552-560.	5.1	9
43	Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International Journal of Urology, 2017, 24, 151-156.	1.0	8
44	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	2.5	7
45	Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2165-2170.	2.5	6
46	Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Scientific Reports, 2016, 6, 19034.	3.3	5
47	Safety of concomitant therapy with radiumâ€223 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	2.3	5
48	Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 165-173.	3.9	4
49	Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. Journal of Urology, 2015, 194, 52-57.	0.4	3
50	Vasectomy: potential links to an increased risk of aggressive prostate cancer?. Expert Review of Anticancer Therapy, 2015, 15, 1123-1125.	2.4	3
51	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. Journal of Urology, 2017, 198, 650-656.	0.4	3
52	Does race predict the development of metastases in men who receive androgenâ€deprivation therapy for a biochemical recurrence after radical prostatectomy?. Cancer, 2019, 125, 434-441.	4.1	3
53	Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia. Infectious Agents and Cancer, 2021, 16, 42.	2.6	3
54	Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1564-1571.	2.5	3

#	Article	IF	CITATIONS
55	Genetic Variants in Predicting Aggressive Prostate Cancer: "Ready for Prime Time?― European Urology, 2014, 65, 1076-1077.	1.9	1
56	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	2.5	1
57	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCHÂdatabase. Cancer Causes and Control, 2021, 32, 189-197.	1.8	1
58	Associations between birth and one year anthropometric measurements and IGF2 and IGF2R genetic variants in African American and Caucasian American infants. Journal of Pediatric Genetics, 2013, 2, .	0.7	1
59	Can We Eat Our Way to a Lower Prostate Cancer Risk, and If So, How?. European Urology, 2014, 65, 895-896.	1.9	O
60	Re: Commentary on "The association between sexual function and prostate cancer risk in US veterans". Asian Journal of Andrology, 2018, 20, 100.	1.6	0
61	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.5	0